surpass cvot tirzepatide C. Michael Gibson MD on X: "SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. # SURPASS-CVOT: Tirzepatide Significantly Reduces Major

Site-specific pegylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects

Try: 3 modest meals and 12 healthy snacks per day Chewing slowly and stopping when you feel comfortably full 4

Genetic predispositions in peptide signaling pathways (GIPR, MC4R, FTO variants) can support more informed conversations with providers about expected dose ranges and titration pace, though they do not predict exact individual response

Synthesis and perspectives Given the high prevalence, strong association with cardiometabolic disease, risk of progression to advanced liver disease, and growing burden alongside rising obesity and diabetes rates, MASLD represents a critical target for early identification, risk stratification, and integrated lifestyle and pharmacologic intervention

The move is an escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound is in a head-to-head contest with the latter's Wegovy (semaglutide) brand